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Impact of investigations in general practice
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subsequently diagnosed with cancer: analysis
of national primary care audit data
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Background: For patients with symptoms of possible cancer who do not fulfil the criteria for urgent referral, initial investigation in
primary care has been advocated in the United Kingdom and supported by additional resources. The consequence of this strategy
for the timeliness of diagnosis is unknown.
Methods: We analysed data from the English National Audit of Cancer Diagnosis in Primary Care on patients with lung (1494),
colorectal (2111), stomach (246), oesophagus (513), pancreas (327), and ovarian (345) cancer relating to the ordering of
investigations by the General Practitioner and their nature. Presenting symptoms were categorised according to National Institute
for Health and Care Excellence (NICE) guidance on referral for suspected cancer. We used linear regression to estimate the mean
difference in primary-care interval by cancer, after adjustment for age, gender, and the symptomatic presentation category.
Results: Primary-care investigations were undertaken in 3198/5036 (64%) of cases. The median primary-care interval was 16 days
(IQR 5–45) for patients undergoing investigation and 0 days (IQR 0–10) for those not investigated. Among patients whose
symptoms mandated urgent referral to secondary care according to NICE guidelines, between 37% (oesophagus) and 75%
(pancreas) were first investigated in primary care. In multivariable linear regression analyses stratified by cancer site, adjustment for
age, sex, and NICE referral category explained little of the observed prolongation associated with investigation.
Interpretation: For six specified cancers, investigation in primary care was associated with later referral for specialist assessment. This
effect was independent of the nature of symptoms. Some patients for whom urgent referral is mandated by NICE guidance are
nevertheless investigated before referral. Reducing the intervals between test order, test performance, and reporting can help reduce
the prolongation of primary-care intervals associated with investigation use. Alternative models of assessment should be considered.
There are an estimated 300 million consultations in general
practice in England annually (90% of all patient contacts with
health care) (Hippisley-Cox and Vinogradova, 2009). A major
challenge for primary-care clinicians is to discriminate, often on
the basis of undifferentiated or non-specific symptoms, between
patients with self-limiting illness and those with significant disease.
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Cancer symptoms typically have low positive predictive values and
present a particular challenge in this respect (Hamilton, 2009).
Nevertheless, prompt identification and referral for investigation of
patients with suspected cancer is a major public and policy concern
(Department of Health, 2007; Macmillan Cancer Support, 2014),
based on a widely held view that delays have a detrimental effect on
outcome. The evidence is not as yet definitive. Although some
studies have shown an association between longer time to
diagnosis and poorer clinical outcomes (Richards et al, 1999;
Torring et al, 2013), confounding by patients with advanced
disease at presentation can make their interpretation problematic
(Neal, 2009). Meanwhile, prolonged time to diagnosis results in
psychological distress and sub-optimal patient experience (Risberg
et al, 1996; Rarer Cancer Foundation, 2011). Clinical guidance for
general practitioners (GPs) on high-risk features warranting urgent
referral for suspected cancer has been produced in a number of
countries, and in England by NICE in 2005 (National Institute for
Health and Care Excellence (2005)). Many cancer patients,
however, present to their GP with lower-risk features (Hamilton,
2010). A more recent approach to improving cancer outcomes in
England has been to increase access for GPs to diagnostic tests
supported by guidance on their use (Department of Health, 2012a).
In the 3 months before diagnosis, Danish patients with cancer
have around 10 times as many diagnostic investigations as the
reference population, some instigated by GPs (Christensen et al,
2012). Most studies of GPs’ use of investigations has addressed
issues of test use (Jellema et al, 2010) and efficiency (Verstappen
et al, 2003; Schoen et al, 2004). It is uncertain, however, whether
initial investigation of cancer symptoms in primary care delays
referral for specialist assessment. This question is central to clinical
practice and cancer diagnosis.
In order to answer the question of whether, in patients with
symptoms suggestive of cancer, primary-care investigations are
associated with less prompt referral, we analysed data from the
English National Audit of Cancer Diagnosis in Primary Care,
conducted during 2009/10 and containing information on 18 879
patients diagnosed with cancer in that period (Rubin et al, 2011).
PATIENTS AND METHODS
The methods used in collection of the source data are described in
detail elsewhere (Rubin et al, 2011). In brief, anonymous data were
collected by GPs or other primary-care professionals in an
estimated total of 1170 general practices (B14% of all practices
in England) that participated voluntarily in an audit of cancer
diagnosis in primary care. All patients of those practices, who were
diagnosed with cancer, typically during a defined period of up to
12 months, were included in the audit. Patients with screen-
detected cancer, in situ cancer, and non-melanoma skin cancer
were excluded. The age, gender, and cancer diagnosis case-mix of
the audited population is representative of the population-based
cancer incidence statistics, and participating practices are similar to
non-participating practices in their (former) cancer networks
(Lyratzopoulos et al, 2013a).
We analysed data on patients with lung (1494), colorectal
(2111), stomach (246), oesophagus (513), pancreas (327), and
ovarian (345) cancer. These six cancer sites were selected because
they each have a range of presenting symptoms from high to low
risk, and because for each there is one or more investigation that
may be appropriately ordered as part of the patient’s assessment in
primary care and that is generally available to GPs in England.
We analysed data on patients aged 15 years or older with
completely observed information on primary-care interval values
from 0 to 730 days (Lyratzopoulos et al, 2013b). We defined
primary-care interval as the period in days from first presentation
to a GP with a relevant symptom to the date of first specialist
referral for further assessment. The audit also collected the date of
the first appointment with a specialist, but did not collect the date
of diagnosis.
Gender and age were recorded from the patient medical records,
the latter categorised for this study into six groups 15–44, 45–54,
55–64, 65–74, 75–4 and 85þ .
Data were extracted from the audit data set in relation to two
questions ‘Did the GP order any investigations’ and ‘If yes, please
list the investigations in order’. Practice staff were asked to identify
any investigations undertaken prior to referral. Responses to the
first question were coded as yes, no, or missing, and responses to
the second question were used to create five binary variables
coding whether or not the patient had had any of five common
investigations: blood test; chest X-ray; ultrasound scan; CT or MRI
scan; endoscopic investigation.
Clinical presentation. Free text audit records in response to the
question ‘What was the main presenting symptom?’ were
categorised in two stages. First, and separately by cancer, the
presenting symptom(s) was classified into between 20 and 37
groups (Appendix Table A1). These were agreed by three clinicians
(GPR, RDN, GL) and then independently assigned by them.
Disagreements were resolved by discussion between coders. Where
more than one symptom was described, the main symptom was
taken as the first stated, unless a NICE Clinical Guideline (CG)27-
mandated (‘alarm’) symptom appeared later in the list.
Second, patients were classified on the basis of their presenting
symptom(s) and age into five groups according to CG27; mandated
referral; possibly mandated referral (insufficient information
provided on qualifying conditions (e.g., severity, duration,
frequency) to be definitive); mandated investigation; possibly
mandated investigation (as above); no mandated action. Some
presenting symptoms (e.g., ascites, haematemesis) were not
specifically mentioned in CG27 as requiring urgent referral, but
the clinical consensus was that this would be best practice. These
were included in the ‘mandated referral’ group. Coding was age
specific for those symptoms for which CG27 recommendations
were age-conditional. For multivariable analysis, ‘possible referrals’
were grouped with ‘no action’ for ovarian and oesophageal cancers
because of small numbers.
Statistical analysis. We describe the primary-care interval dis-
tribution using the mean, median, 25th, 75th, and 90th centiles.
Stratified by cancer diagnosis, we calculated the percentages of
patients investigated by their GP in each of the five NICE CG27
referral recommendation groups.
We calculated the mean difference in primary-care interval
among those patients investigated in primary care and those who
were not. To determine whether the association between primary-
care investigations and primary-care interval can be attributed to
different clinical presentations (i.e., whether patients who are most
likely to be investigated are simply those who present with non-
specific symptoms and have a longer primary-care interval for this
reason), we used linear regression to estimate the mean difference
in primary-care interval by investigation status, adjusting for age,
gender, and the NICE referral category, separately by cancer.
95% Confidence intervals were estimated using bias corrected
and accelerated bootstrap estimation, and where they exclude zero,
the differences between the two groups were taken to be significant
at Po0.05. Analyses were repeated for 99.99% confidence
intervals.
We performed a number of sensitivity analyses investigating
the impact of how the primary-care interval, primary-care
investigation use and clinical presentation were parameterised
(see Appendix Tables for details). Further, we performed a
supplementary analysis to explore the possibility that primary-
care investigation may decrease the referral interval (defined as the
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number of days between referral from primary care and first
patient contact in secondary care). We therefore explored the
adjusted association of overall pre-hospital interval (defined as the
total time from first presentation to primary care to first being seen
in secondary care, i.e., referral interval plus primary-care interval)
with investigation use.
RESULTS
The derivation of the analysis sample is shown in Figure 1. In
descriptive analyses, primary-care investigations were undertaken
in 3198/5036 of included cases (64%), ranging from 43% for
oesophageal cancer to 80% for lung cancer. The median primary-
care interval across all six cancer sites was 16 (IQR 5–45) days for
those who had one or more investigation, and 0 (IQR 0–10) days
for those who had no investigation. The corresponding mean
intervals were 41 days and 17 days, and did not differ by age or
gender. The difference in the median interval by investigation
status was considerably greater at the 75th (10 days non-
investigated, 44 days investigated patients) and 90th centiles (45
days and 106 days, respectively) (Table 1).
In unadjusted analyses, individual investigations lengthened the
mean primary-care interval by between 5 days (chest X-ray) and 32
days (endoscopy), whereas undertaking more than one test in
primary care added a mean of 8 days (Table 2). For individual
cancer sites, any investigation significantly extended the mean
primary-care interval by between 20 days (ovarian) and 30 days
(stomach) (Table 2). When individual cancers were considered by
NICE referral category, investigation was more likely if NICE
CG27 mandated this or if no action was mandated. The proportion
of patients presenting with symptoms for which NICE CG27
mandates urgent referral was 10%, 9%, 5%, 64%, 24%, and 37% for
colorectal, ovarian, lung, oesophageal, pancreatic, and stomach
cancer, respectively. Nevertheless, a substantial proportion of
patients whose symptoms mandated urgent referral were investi-
gated in primary care, ranging from 37% (oesophagus) to 75%
(pancreas) (Table 3).
In linear regression analyses, stratified by cancer, that adjusted
for age, sex, and the NICE referral category, adjustment for these
factors explained very little of the mean observed additional days
associated with investigation, but the effect for pancreatic cancer
ceased to be significant (Table 4). Alternative parameterisations of
the primary-care interval, investigation use, or clinical presentation
categories made minimal difference to these findings (Appendix
Tables A3–A5).
Among those patients for whom data on number of consulta-
tions prior to referral were available, 965/2095 (46.1%) of those
consulting once were investigated, while 1058/1240 (85.3%) of
those consulting 3þ times were investigated.
Finally, in order to address the possibility that longer primary-
care intervals might be offset by shorter referral intervals, we
examined the association between investigations in primary care
and the combined primary care and referral interval (i.e., from first
presentation in primary care to first being seen in a specialist
clinic). For all cancers, except pancreatic cancer, the pre-hospital
interval is longer among investigated patients, compared with
those who were not investigated. We find no evidence that longer
primary-care intervals are offset by shorter referral intervals in
patients who are investigated in primary care (Appendix Table
A6). Because date of diagnosis did not form part of the data items
collected for the audit, we were unable to examine the effect of
investigations on total diagnostic interval.
DISCUSSION
We found that for six specified cancers, investigation in primary
care of the presenting symptom(s) was associated with later referral
for specialist assessment. This difference in the mean primary-care
interval ranged from an additional 20 to 30 days depending on the
cancer site, and was independent of whether the patient presented
with alarm symptoms. For four of the six cancers studied, the
difference increased with the number of tests undertaken.
The principle that patients with symptoms are initially assessed in
primary care in order that only a proportion are then more
extensively assessed by specialists (the gatekeeping function) is a key
feature of health-care systems in which primary care features
strongly. It contributes to their better health outcomes and efficiencies
(Starfield et al, 2005), although an ecological association with poorer
6307 Patients in the NACDPC database
with 6 cancers; colorectal, ovarian, lung,
oesophageal, pancreatic, stomach
134 Patients with age < 15 (n=1) or missing
age (n=133)
6173 Patients with a valid age > 15 years
1100 Patients with missing primary care
interval
5073 Patients with a vaild outcome
measure (primary care interval)
37 Patients with missing information on GP
requested investigations
5036 Patients included in the final analysis
sample
Figure 1. Flow diagram: derivation of the analysis sample.
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cancer 1-year survival has also been described (Vedsted and Olesen,
2011). Investigation in primary care is most strongly associated with
perceived medical need, although a minority of investigations are a
consequence of patient preference (Little et al, 2004). Where the
alternative is specialist referral, investigation in primary care may
result in the primary-care interval being prolonged, since
additional consultations are needed to communicate results, and
multiple consultations are associated with longer primary-care
intervals (Lyratzopoulos et al, 2013b). We found that 85% of
patients consulting three or more times had undergone investiga-
tion, compared with 46% of those consulting once. The literature is
sparse on the effect of investigations in primary care on time to
diagnosis, although a study of patients with colorectal cancer found
that those who were not investigated by the faecal occult blood test
had a significantly shorter median diagnostic interval than those
who were (Hogberg et al, 2013). Further, a qualitative study of
patients with testicular cancer identified waiting time for GP-
requested ultrasonography as a factor in late diagnosis (Chapple
et al, 2004). However, failure to investigate may be also associated
with referral being deferred. In a study of GP-reported quality
deviations in 5711 patients with cancer, failure to order relevant
investigations was associated with a prolonged diagnostic interval
(Jensen et al, 2014), whereas diagnostic delay for tuberculosis has
been associated with failure of the first doctor consulted to order a
sputum test or chest X-ray (Calder et al, 2000).
Strategies have been developed to expedite the investigation of
patients with symptoms that could indicate cancer. In Denmark,
ambulatory care facilities exist for the prompt investigation of
patients with non-specific symptoms, alongside an urgent referral
pathway for those with higher-risk symptoms (Danish National
Board of Health, 2010) Walk-in access to chest X-ray for
symptomatic members of the public aged 450 years has been
provided through a local initiative in Leeds, UK, resulting in 8.6%
of all community-ordered chest X-rays being taken this way
(Cheyne et al, 2012). Dedicated centres that allow patients to access
specialist assessment without physician referral have also been
proposed by a panel of cancer experts in the United States, as a
response to their Institute of Medicine report ‘Crossing the Quality
Chasm’ (Bowles et al, 2008). The initiatives described address a
range of constraints to prompt diagnosis, and they operate within
complex health systems. Their impact can only be fully understood
in the context of the overall diagnostic pathway, something we
were unable to do in this study.
Strengths and limitations. This is the first study to explicitly
determine the effect of GP-initiated investigations on speed of
referral for specialist assessment. Its strengths include the relatively
large number of cases for each cancer site, the completeness of data
on presenting symptom(s) and consultations, and the direct
extraction of information from the primary-care record. The study
team included experienced clinicians, ensuring that the complex
task of coding clinical data was accurately completed.
There are several limitations that we acknowledge. Because
participation of general practices in the audit was voluntary and
potentially biased towards those most interested in cancer care, the
findings may represent ‘better’ practice. However, the audit patient
population was similar to the incident cancer cases in England
(Rubin et al, 2011) while the characteristics of participating
practices were similar to non-participating practices of the same
(former) cancer network (Lyratzopoulos et al, 2013b). Never-
theless, these practices may have been more interested in cancer
diagnosis and management and more likely to investigate patients
with suspicious symptoms. Practices were typically required to
audit a continuous sample of cases occurring in a specified period,
and there was no evidence of significant exclusion of cases (Rubin
et al, 2011).
Data were extracted from clinical records and hospital
correspondence. There was no validation of the data, but in all
cases data were reviewed at a practice meeting and checked for
completeness and face validity by a cancer network clinical lead.
There is scope for errors of interpretation during data extraction,
for example, in deciding on the date of first consultation. The
potential sources of error in studies of diagnostic intervals have
been well described (Weller et al, 2012), but the methodology used
by the audit conformed to best practice in the field Weller et al,
2012). Finally, 1100 (17.9%) cases were excluded because both of
the dates required to estimate the primary-care interval were not
available. Many of these were patients whose pathway to diagnosis
Table 1. Patient characteristics, mean and median (percentile) primary-care interval
Primary-care interval
N Mean Median 25th Percentile 75th Percentile 90th Percentile
All 5036 32.5 8 0 34 87
Sex
Female 2413 33.1 9 0 36 88
Male 2623 31.9 8 0 32 85
Age
15–44 150 36.9 7.5 0 43 113
45–54 405 30.3 8 0 34 75
55–64 1030 31.1 8 0 33 85
65–74 1503 32.0 8 0 34 83
75–84 1430 33.6 9 0 36 88
85þ 518 34.2 7 0 32 100
Cancer diagnosis
Colorectal 2111 33.0 6 0 30 94
Ovarian 345 21.5 7 0 25 54
Lung 1494 34.5 13 3 39 83
Oesophageal 513 26.3 6 0 31 75
Pancreatic 327 33.0 7 0 32 96
Stomach 246 43.2 13 0 58 132
Investigations in primary care
No 1838 17.4 0 0 10 44
Yes 3198 41.2 16 5 45 106
GP investigations and time to diagnosis BRITISH JOURNAL OF CANCER
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bypassed primary care, for example, through direct presentation to
an emergency department. Others may have been seen by the GP,
but the omission of dates of the first encounter and/or referral was
not identified during the checking process prior to submission of
data to the audit.
All investigations included were part of the primary-care
appraisal process, but no judgement was made on their appro-
priateness or their context within the episode of care. It is possible
that some were unhelpful or irrelevant to the diagnostic process
and unnecessarily prolonged the primary-care interval. Details of
the precise nature of blood or urine tests or the sites examined by
CT, MRI, or endoscopy were not a specific requirement of
practices participating in the audit.
Because the audit data were provided in an anonymous form,
we were unable to link them to cancer registration and hospital
record-derived data. This would have allowed us to determine, for
those patients not investigated in primary care, whether investiga-
tion(s) were then undertaken in secondary or tertiary care and the
effect of investigations in different settings on the total diagnostic
interval. However, we observed that use of investigations, although
adding to the length of the primary-care interval, did not result in a
shorter referral interval. Moreover, for the hypothesis to be true
that patients investigated in primary-care experience shorter
secondary-care delays, and therefore no overall lengthening of
the total diagnostic interval, either or both of the referral interval
and the within-hospital interval to diagnosis would need to be
substantially shorter for those patients with primary-care investi-
gations compared with those without. These conditions are
unlikely. First, we have observed a net lengthening of referral
interval resulting from investigations for five out of six cancers.
Second, as use of investigations is associated with extending of the
primary-care interval by a median of þ 16 days and a mean of
þ 24 days, within-hospital diagnostic processes would need to be
extraordinarily fast to compensate for these prolonged intervals. It
should also be noted that in 2011/12 87.3% of patients commenced
treatment within 62 days of referral, and 98.4% commenced
treatment within 31 days of a diagnosis being made (Department
of Health, 2012b). Moreover, the most frequent primary-care
investigations were blood tests and chest X-rays, tests that do not
typically provide the definitive diagnostic information necessary to
establish the diagnosis of cancer, and would be unlikely to result in
any substantial shortening of diagnostic intervals within secondary
or tertiary care.
We selected the NICE referral category as our primary method
for categorising patients’ presenting symptoms. We adjusted for
symptom status using a range of complementary analytical
approaches, all of which indicated that the degree of confounding
by symptom status (in respect of the association between
investigation and prolonged primary-care interval) is trivial. In
other words, whether patients present with non-specific symptoms
or obvious alarm symptoms, investigations are always associated
with a longer primary-care interval.
Implications for practice. Our findings are generalisable to health
systems in which GPs act as gatekeepers to specialist care, but may
be modified by differences in access to diagnostic tests. A
substantial proportion of patients underwent investigation when
their symptoms fulfilled NICE CG27 criteria for urgent referral.
There are several possible explanations for this. Disparaging views
from specialists about ‘abuse’ by GPs of the urgent referral pathway
Table 3. Use of primary-care investigations and the NICE guideline referral category based on clinical presentation, by cancer
GP investigations performed
Action specified by NICE guidelines under NICE CG27 based
on patient characteristics and clinical presentation
All
N N %
Colorectal Mandated referral under NICE guidelines (or good clinical practice) 208 99 47.6
Possible referral under NICE guidelines 1105 581 52.6
Mandated investigation under NICE guidelines 200 90 45.0
Possible investigation under NICE guidelines 0
No action under NICE guidelines 598 374 62.5
Ovarian Mandated referral under NICE guidelines (or good clinical practice) 31 12 38.7
Possible referral under NICE guidelines 5 0
Mandated investigation under NICE guidelines 26 16 61.5
Possible investigation under NICE guidelines 0
No action under NICE guidelines 283 212 74.9
Lung Mandated referral under NICE guidelines (or good clinical practice) 76 39 51.3
Possible referral under NICE guidelines 0
Mandated investigation under NICE guidelines 223 195 87.4
Possible investigation under NICE guidelines 916 779 85.0
No action under NICE guidelines 279 187 67.0
Oesophageal Mandated referral under NICE guidelines (or good clinical practice) 328 121 36.9
Possible referral under NICE guidelines 9 0 0.0
Mandated investigation under NICE guidelines 0
Possible investigation under NICE guidelines 69 36 52.2
No action under NICE guidelines 107 63 58.9
Pancreatic Mandated referral under NICE guidelines (or good clinical practice) 79 59 74.7
Possible referral under NICE guidelines 100 65 65.0
Mandated investigation under NICE guidelines 0
Possible investigation under NICE guidelines 0
No action under NICE guidelines 148 122 82.4
Stomach Mandated referral under NICE guidelines (or good clinical practice) 92 45 48.9
Possible referral under NICE guidelines 21 15 71.4
Mandated investigation under NICE guidelines 0
Possible investigation under NICE guidelines 40 26 65.0
No action under NICE guidelines 93 62 66.7
Abbreviations: GP¼general practitioner; NICE¼National Institute for Health and Care Excellence.
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may make some prefer to have additional evidence in the form of a
confirmatory test result before making a referral (Mathew and
Desai, 2009). The NICE criteria typically represent a risk of cancer
in the region of 5–10%, the large majority not having the disease,
and some GPs may use investigations as means of increasing the
probability of cancer prior to making a decision about referral. It is
also possible that some patients present in a context that causes the
GP to modify their preferred course of action. For example, the
patient may have been investigated in the past for the same
problem, have severe co-morbidities, or may be reluctant to be
referred to a specialist. Some GPs may consider it desirable, or have
been advised that it is, for the results of baseline investigations to
be available at the first specialist attendance (Barking, Havering
and Redbridge University Hospital, 2014). Significant event
analyses and case-note review studies are required to further
establish the circumstances surrounding such ‘guideline violations’
(Mitchell et al, 2013; Singh et al, 2013).
Finally, certain investigations available to GPs are the definitive
diagnostic tests, e.g., gastroscopy for suspected oesophagogastric
cancer, and may be as readily available in primary as in specialist
care. Other diagnostic tests, however, take longer to complete when
ordered from primary care and may not be sufficiently compre-
hensive. In England, the median time from request to test for non-
obstetric ultrasound investigation is longer for GP requests (19–27
days) than for all request sources combined (12–16 days) (NHS
England, 2013). If investigations are undertaken in patients for
whom urgent referral is indicated, the request should be
concurrent with referral.
Because tests ordered in primary care may not be done or
reported as promptly as those ordered from secondary care, our
findings point to a need for investigative services to be provided to a
comparable standard regardless of source of request. This should be
accompanied by improved systems in primary care that ensure that a
patient is rapidly reviewed once results are received. They also
provide some support for models of service delivery in England
that permit the rapid specialist assessment of patients with lower-
risk symptoms, either by a lowering of the thresholds for
urgent (2 weeks) referral for suspected cancer or the provision of
diagnostic centres.
Time may be used as a diagnostic tool in primary care
(Heneghan et al, 2009). Symptoms are seen by GPs at an earlier
stage of development than in secondary care, and time allows
the clinician to observe whether relatively undifferentiated
symptoms develop more specific characteristics or resolve
spontaneously. Investigations may form a part of this temporising
approach while also being part of a safety-netting strategy (Almond
et al, 2009).
These findings are the first step in determining the most
effective diagnostic strategies for managing patients with
symptomatic presentation of cancer. It will be important to
understand the impact of primary-care investigation on second-
ary-care intervals, since these may plausibly be shortened, and on
total diagnostic delay. Until then, no firm recommendations can
be made on the merits or demerits of primary-care investigation.
There is a need to understand the comparative clinical and
health economic efficiency of strategies that encourage early
primary-care investigation, compared with those that encourage
either expectant management with limited testing and urgent
referral if symptoms persist or worsen, or early referral without
prior investigation.
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Table 4. Mean additional length of primary-care interval associated with primary-care investigations after adjustment for age,
sex and NICE guideline referral category
Mean additional primary-care interval (in days) among
patients where investigations were performed
Number of cases Unadjusted
Adjusted for age, sex, and
clinical presentation P-valuea
Colorectal Not investigated 967 Reference Reference Po0.0001
Investigated 1144 26.7 (20.8–33.0) 25.7 (19.5–31.7)
Ovarianb Not investigated 105 Reference Reference Po0.0001
Investigated 240 20.1 (13.6–27.5) 18.4 (12.2–25.5)
Lung Not investigated 294 Reference Reference Po0.0001
Investigated 1200 21.8 (15.3–27.6) 23.6 (16.8–30.0)
Oesophagealb Not investigated 293 Reference Reference Po0.0001
Investigated 220 25.3 (16.7–34.8) 22.3 (13.2–32.4)
Pancreaticc Not investigated 81 Reference Reference P40.05
Investigated 246 23.2 (5.0–38.1) 17.1 ( 1.9–30.6)
Stomach Not investigated 98 Reference Reference Po0.0001
Investigated 148 30.4 (15.1–48.2) 29.3 (14.0–45.8)
Abbreviation: NICE¼National Institute for Health and Care Excellence.
a95% Confidence intervals were estimated using bias corrected and accelerated bootstrap. The P-value (P40.05) presented for pancreatic cancer reflects that this 95% confidence interval
crosses zero. For all other cancers bias corrected and accelerated bootstrap 99.99%confidence intervals were re-estimated for the same model and these also did not cross zero, Po0.0001 is
correspondingly presented.
b‘Possible referrals’ grouped with ‘No action’ in multivariable analysis because of small numbers.
cAge 15–44 years grouped with age 55–64 years because of small numbers.
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APPENDIX
Table A1. Symptom groups by cancer
Oesophageal and
gastric cancer Lung cancer Ovarian cancer Colorectal cancer Pancreatic cancer
Dysphagia Haemoptysis Ultrasound suggestive of ovarian
cancer
Rectal bleeding Obstructive jaundice
Early satiety Chest/shoulder pain Post-menopausal bleeding Altered bowel habit (to
looser stool)
Thromboembolic disease
Nausea, vomiting Dyspnoea Persistent intermenstrual bleeding
(with a negative pelvic examination)
Abdominal mass Bleeding per rectum/melaena
Dyspepsia Weight loss Abdominal or pelvic mass not of
gastroenterological or urological
origin
Rectal mass Diabetic ketoacidosis/new onset dia-
betes/loss of known diabetes control
Reflux Chest signs Abdominal or pelvic pain or
discomfort
Anaemia Altered bowel habit
Pain (epigastric,
abdominal, chest)
Hoarseness Abdominal bloating/distension/swel-
ling/fullness
Weight loss Nausea and vomiting
Anorexia Clubbing Urinary symptoms (including incon-
tinence and retention)
Abdominal pain or
tenderness
Gastro-oesophageal reflux disease
Fatigue, malaise Chest X-ray/supra-
clavicular lymph
nodes
Unexplained weight loss Bloating/distension General malaise
Weight loss Cough Fatigue/tiredness/malaise/unwell/
exhaustion
Malaise Bloating
Bowel disturbance Features suggesting
metastases
Change in bowel habit to diarrhoea or
alternating diarrhoea/constipation
Asymptomatic or inciden-
tal, including surveillance
Biliary colic
Iron deficiency
anaemia
Abnormal chest
X-ray
Acute surgical/medical
emergency
Cough/shortness of breath
Haematemesis/
melaena
Superior vena cava
obstruction
Vaginal discharge or other abnormal
vaginal bleeding
Constipation Weight loss
Dizziness Stridor Anaemia Nausea/vomiting Urinary tract infection/other urinary
symptoms
Upper abdominal
mass
Loss of appetite Chest symptoms Other pain anaemia
Asymptomatic or
incidental finding
Thrombocytosis Pulmonary embolus or deep vein
thrombosis
Defaecation problems Back pain
Pain (other) Abnormal
spirometry
Infertility Anorexia Abdominal pain
Barrett’s Asymptomatic or
incidental
Nausea and/or vomiting Mucus Abdominal mass
Respiratory
symptoms
Hyponatraemia Asymptomatic or incidental Collapse Asymptomatic or incidental
Bloating Respiratory infection Ascites Respiratory symptoms Anorexia
Belching Exacerbation of
chronic obstructive
pulmonary disease
Anorexia Haemorrhoids Dysphagia
Throat symptoms Abdominal pain Other/missing/not stated/not known Urinary symptoms Change in bowel habit
Hiatus hernia Back pain Liver Dyspepsia
Odynophagia Liver symptoms/signs Upper gastrointestinal
symptoms
Other/missing/not
stated/not known
Confusion Disordered sensation
lower limbs
Liver
Malaise Ascites Pancreatitis/chronic
Collapse Colitis/inflammatory
bowel disease
Steatorrhoea
Change in bowel
habit
Other/missing/not stated/
not known
Lymphadenopathy
Pain (other) Other/missing/not stated/not known
Urinary symptoms
Headache
Lower limb oedema
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Sweats/fever
Anaemia
Upper gastrointest-
inal symptoms
Lump
Nausea or vomiting
Cardiac
abnormalities
Neurological
ENT symptoms
Other/missing/not
stated/not known
Abbreviation: ENT¼ ear, nose and throat.
Table A2. NICE guideline referral categories based on clinical presentation
Mandated referral under NICE guidelines (or good clinical practice) Clear evidence for mandated urgent referral as per NICE CG27
Good clinical medicine would mandate urgent referral
Possible referral under NICE guidelines
Possible mandated urgent referral as per NICE CG27—but duration dependent
Possible mandated urgent referral as per NICE CG27—but severity dependent
Possible mandated urgent referral as per NICE CG27—but location dependent
Possible mandated urgent referral as per NICE CG27—but dependent upon
sense of abnormality
Possible mandated urgent referral as per NICE CG27—other
Mandated investigation under NICE guidelines Clear evidence of mandated investigation as per NICE CG27
Possible investigation under NICE guidelines
Possible mandated investigation as per NICE CG27—but duration dependent
Possible mandated investigation as per NICE CG27—but severity dependent
Possible mandated investigation as per NICE CG27—but location dependent
Possible mandated investigation as per NICE CG27—but dependent upon
sense of abnormality
Possible mandated investigation as per NICE CG27—other
No action under NICE guidelines No mandated action from NICE CG27
Abbreviation: NICE¼National Institute for Health and Care Excellence.
Sensitivity analysis
We performed several sensitivity analyses for key analytical
aspects, using alternative parameterisations of the three variables:
 Primary-care interval
 Investigation use in primary care
 Clinical presentation
Primary-care interval is positively skewed, with a large number of
zero values. The analysis (presented in the main text) examines
‘mean differences’ in primary-care interval associated with investiga-
tion use. Although the use of bootstrap estimation means that
inference is appropriate, we also performed a sensitivity analysis
based on a binary categorisation of primary-care interval into 0–14
and 15þ days. Results are presented in Appendix Table A3.
Investigation use can be parameterised as a binary yes/no
variable (as in the main text)—or as an ordered categorical variable
based on the number of investigations (used in sensitivity analysis).
Specifically, the number of investigations was parameterised as an
ordered categorical variable (0, 1, 2 or more investigations) based
on counts of the five individual investigations (blood tests, chest
X-rays, ultrasound, CT/MRI, or endoscopy). Results are presented
in Appendix Table A4.
In the main analysis presented, we adjust for clinical presenta-
tion using five groups based on NICE guideline referral categories
(Appendix Table A2). In sensitivity analysis adjustment for clinical
presentation was made on the basis of presenting symptom(s)
(Appendix Table A1) and based on this classification, but allowing
the effect of symptom to vary by age. We also explored adjusting
for the more detailed 14-group classification based on NICE
guidelines (Appendix Table A2). Results are presented in Appendix
Table A6.
Supplementary analysis
We performed a supplementary analysis to explore the
possibility that primary-care investigation may decrease the
referral interval (defined as the number of days between referral
from primary care and the first patient contact in secondary
care). If this hypothesis were true, it might offset the differences
in primary-care interval. We therefore explored the adjusted
association of overall pre-hospital interval (defined as the total
time from first presentation to primary care to first being seen
in secondary care, i.e., referral interval plus primary-care
interval) with investigation use. Results are presented in
Appendix Table A6.
For ovarian and oesophageal cancers ‘possible referrals’
were grouped with ‘no action’ in multivariable analysis
because of small numbers, similarly age 15–44 years is grouped
with age 55–64 years for pancreatic cancer because of small
numbers.
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Table A3. Sensitivity analysis using alternative parameterisation of primary-care interval
Number of cases
Adjusted for age, sex, and the NICE
referral category based on
presenting symptoms
OR (95% CI) for 15þ days primary-care
interval (compared with 0–14 days)
adjusted for age, sex, and clinical presentation P-value
Colorectal Not investigated 967 Reference Reference o0.001
Investigated 1144 25.7 (19.5–31.7) 4.6 (3.7–5.6)
Ovarian Not investigated 105 Reference Reference o0.001
Investigated 240 18.4 (12.2–25.5) 4.2 (2.3–7.9)
Lung Not investigated 294 Reference Reference o0.001
Investigated 1200 23.6 (16.8–30.0) 3.8 (2.8–5.2)
Oesophageal Not investigated 293 Reference Reference o0.001
Investigated 220 22.3 (13.2–32.4) 4.1 (2.8–6.1)
Pancreatic Not investigated 81 Reference Reference o0.001
Investigated 246 17.1 ( 1.9–30.6) 4.4 (2.1–9.2)
Stomach Not investigated 98 Reference Reference o0.001
Investigated 148 29.3 (14.0–45.8) 5.7 (3.1–10.6)
Abbreviations: CI¼ confidence interval; NICE¼National Institute for Health and Care Excellence; OR¼odds ratio. Results presented in bold italics are those from Table 4 This sensitivity
analysis finds that investigation use is associated with longer primary-care interval for all six cancers when using a logistic model.
Table A4. Sensitivity analysis using alternative parameterisation of investigation use in primary care
Number
of cases
Adjusted for age, sex,
and the NICE referral
category based on
presenting symptoms
Number
of cases
Adjusted for age,
sex, and the NICE
referral category
based on presenting
symptoms
Colorectal Not investigateda 967 Reference No investigationsa 1031 Reference
Investigated 1144 25.7 (19.5–31.7) One 923 21.3 (15.1–30.0)
Twoþ 157 43.5 (28.3–58.2)
Ovarian Not investigated 105 Reference No investigations 108 Reference
Investigated 240 18.4 (12.2–25.5) One 147 20.1 (11.0–30.6)
Twoþ 90 13.6 (6.0–21.2)
Lung Not investigated 294 Reference No investigations 312 Reference
Investigated 1200 23.6 (16.8–30.0) One 809 17.0 (6.9–24.7)
Twoþ 373 16.2 (6.6–24.8)
Oesophageal Not investigated 293 Reference No investigations 315 Reference
Investigated 220 22.3 (13.2–32.4) One 162 17.1 (7.7–28.8)
Twoþ 36 29.9 (10.3–58.1)
Pancreatic Not investigated 81 Reference No investigations 82 Reference
Investigated 246 17.1 ( 1.9–30.6) One 148 4.8 ( 14.4–16.7)
Twoþ 97 41.3 (20.2–62.5)
Stomach Not investigated 98 Reference No investigations 104 Reference
Investigated 148 29.3 (14.0–45.8) One 112 21.2 (6.2–35.8)
Twoþ 30 56.0 (16.7–107.8)
Abbreviations: CT¼ computed tomography; MRI¼magnetic resonance tomography; NICE¼National Institute for Health and Care Excellence. aThe numbers in these two groups (for all
cancers) are slightly different as column 3 includes patients who have had any investigation in primary care, but counts in column 6 are based only on the five listed investigations (blood tests,
chest X-rays, ultrasound, CT/MRI, or endoscopy). Results presented in bold italics are those from Table 4 With a single exception (pancreatic cancer) primary-care investigations were associated
with longer primary-care intervals. For colorectal, oesophageal, pancreatic and stomach cancer, primary-care intervals were longer among people who had two or more primary-care
investigations, compared with those who had one. For lung and ovarian cancer. investigation use was associated with longer primary-care interval, but delay was not additionally longer among
people with two or more primary-care investigations, compared with only one.
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Table A5. Sensitivity analysis using alternative parameterisation of clinical presentation (symptom category) or the
NICE referral category
Number
of cases
Adjusted for age, sex,
and main (5) NICE
referral categories
based on presenting
symptoms
Adjusting for
age and sex and
detailed (14)
NICE referral
categories
Adjusting age and
sex and for clinical
presentation using
main presenting
symptom
Adjusting for age and sex and for
clinical presentation using main
presenting symptom (allowing the
effect of symptom to vary by age)
Colorectal Not investigated 967 Reference Reference Reference Reference
Investigated 1144 25.7 (19.5–31.7) 24.6 26.5 26.2
Ovarian Not investigated 105 Reference Reference Reference Reference
Investigated 240 18.4 (12.2–25.5) 18.5 17.8 18.1
Lung Not investigated 294 Reference Reference Reference Reference
Investigated 1200 23.6 (16.8–30.0) 23.9 20.1 20.8
Oesophageal Not investigated 293 Reference Reference Reference Reference
Investigated 220 22.3 (13.2–32.4) 22.7 23.4 23.0
Pancreatic Not investigated 81 Reference Reference Reference Reference
Investigated 246 17.1 ( 1.9–30.6) 14.9 13.9 16.0
Stomach Not investigated 98 Reference Reference Reference Reference
Investigated 148 29.3 (14.0–45.8) 28.4 27.7 28.0
Abbreviation: NICE¼National Institute for Health and Care Excellence. Results presented in bold italics are those from Table 4. Different approaches to adjusting for clinical presentation in
different ways have minimal impact on the association between primary-care investigation use and primary-care interval.
Table A6. Supplementary analysis. The association between investigation use and referral interval (defined as period
from day of referral to day when patient was first seen at hospital)
Primary-care interval Referral interval Pre-hospital interval
Number
of cases
Adjusted for age, sex,
and the NICE referral
category of presenting
symptoms
Number
of cases
Adjusted for age, sex,
and the NICE referral
category of presenting
symptoms
Number
of cases
Adjusted for age, sex,
and the NICE referral
category of presenting
symptoms
Colorectal Not investigated 967 Reference 946 Reference 946 Reference
Investigated 1144 25.7 (19.5–31.7) 1120 5.1 (2.1–8.7) 1120 28.4 (21.9–34.9)
Ovarian Not investigated 105 Reference 101 Reference 101 Reference
Investigated 240 18.4 (12.2–25.5) 236 1.6 ( 5.0–4.6) 238 18.7 (10.0–27.4)
Lung Not investigated 294 Reference 290 Reference 290 Reference
Investigated 1200 23.6 (16.8–30.0) 1165 4.5 ( 1.6–10.1) 1165 28.6 (19.4–36.8)
Oesophageal Not investigated 293 Reference 283 Reference 283 Reference
Investigated 220 22.3 (13.2–32.4) 215 4.5 ( 2.2–13.3) 215 29.1 (18.2–42.5)
Pancreatic Not investigated 81 Reference 78 Reference 78 Reference
Investigated 246 17.1 ( 1.9–30.6) 241  9.4 ( 33.2–3.1) 241 7.4 ( 15.6–30.3)
Stomach Not investigated 98 Reference 95 Reference 95 Reference
Investigated 148 29.3 (14.0–45.8) 141 11.9 (5.1–26.7) 141 41.8 (21.5–63.4)
Abbreviation: NICE¼National Institute for Health and Care Excellence. Results presented in bold italics are those from Table 4.
In order to address the possibility that longer primary-care intervals
might be offset by shorter referral intervals among investigated
patients, we examined the association between investigations in
primary care and the referral interval, and the combined primary
care and referral interval (i.e., from first presentation in primary care
to first being seen in a specialist clinic).
Although the differences in referral interval among
investigated and non-investigated patients are small they are
positive for all cancers except for pancreatic (i.e., referral intervals
are not shorter among investigated patients). Consequently,
the pre-hospital interval is longer among investigated patients,
compared with those who were not investigated for all cancers
except pancreatic cancer. Therefore, overall there is no evidence
that longer primary-care intervals are offset by shorter
referral intervals among patients who were investigated in primary
care.
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